Bristol Myers Squibb Company $BMY Stock Sold by CenterBook Partners LP

Key Points

• CenterBook Partners cut its Bristol Myers Squibb stake by 28.6% in the third quarter, selling 16,668 shares and retaining 41,540 shares valued at about $2.59 million.
• Bristol Myers beat quarterly estimates, reporting EPS of $1.35 versus $1.10 expected and revenue of $13.07 billion, up 6.9% year over year. Analysts’ consensus rating was “Hold,” with an average price target of $65.46.
• Director Julia A. Haller sold 3,800 shares, while the company’s quarterly dividend of $0.63 per share equates to an annualized yield of about 4.1% at the reported share price.

CenterBook Partners LP trimmed its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 28.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,540 shares of the biopharmaceutical company's stock after selling 16,668 shares during the quarter. CenterBook Partners LP's holdings in Bristol Myers Squibb were worth $2,592,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BMY. Davis Asset Management L.P. bought a new position in shares of Bristol Myers Squibb in the second quarter worth approximately $27,000. Addison Advisors LLC purchased a new stake in shares of Bristol Myers Squibb in the second quarter worth $32,000. William Mack & Associates Inc. bought a new stake in shares of Bristol Myers Squibb during the 3rd quarter valued at $35,000. Groupe la Francaise raised its position in shares of Bristol Myers Squibb by 562.9% during the 2nd quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 501 shares during the period. Finally, Kilter Group LLC purchased a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at $35,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Bristol Myers Squibb

In other news, Director Julia A. Haller sold 3,800 shares of the company's stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the sale, the director directly owned 30,279 shares of the company's stock, valued at $1,916,963.49. This represents a 11.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Phil M. Holzer sold 500 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares of the company's stock, valued at $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.05% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Bank of America reaffirmed a "buy" rating on shares of Bristol Myers Squibb in a report on Friday, October 30th. TD Cowen initiated coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They set a "buy" rating for the company. Royal Bank Of Canada reiterated a "sector perform" rating on shares of Bristol Myers Squibb in a research report on Monday, October 19th. Wells Fargo & Company lowered their target price on shares of Bristol Myers Squibb from $65.00 to $60.00 and set an "equal weight" rating on the stock in a report on Tuesday, October 13th. Finally, JPMorgan Chase & Co. upped their target price on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an "overweight" rating in a research report on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of "Hold" and an average target price of $65.46.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
• Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
• Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
• Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
• Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Bristol Myers Squibb Trading Up 0.1%

Shares of Bristol Myers Squibb stock opened at $62.20 on Monday. Bristol Myers Squibb Company has a twelve month low of $45.26 and a twelve month high of $68.64. The company has a quick ratio of 1.44, a current ratio of 1.59 and a debt-to-equity ratio of 1.79. The business has a 50-day moving average price of $62.34 and a 200-day moving average price of $60.11. The firm has a market cap of $127.15 billion, a price-to-earnings ratio of 13.79, a PEG ratio of 0.32 and a beta of 0.20.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, topping analysts' consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The company had revenue of $13.07 billion for the quarter, compared to the consensus estimate of $12.72 billion. During the same period in the previous year, the business earned $1.63 earnings per share. The firm's revenue for the quarter was up 6.9% on a year-over-year basis. Equities research analysts anticipate that Bristol Myers Squibb Company will post 6.45 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. Bristol Myers Squibb's payout ratio is presently 55.88%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company's medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.